Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23645415 | 0.88 | KMT2A (0.38) | KMT2AMAPTFAAHCYP1A2GAA | |
| SCHEMBL28626441 | 0.83 | KDM4E (0.32) | KDM4E | |
| SCHEMBL23645339 | 0.81 | FAAH (0.34) | KMT2AMAPTFAAHCYP1A2GAA | |
| SCHEMBL23645360 | 0.81 | FAAH (0.36) | KMT2AMAPTFAAHCYP1A2GAA | |
| SCHEMBL23645323 | 0.79 | ATM (0.38) | KMT2AMAPTFAAHCYP1A2GAA | |
| SCHEMBL23645401 | 0.78 | KMT2A (0.40) | KMT2AMAPTFAAHGAAKDM4E | |
| SCHEMBL23645420 | 0.76 | L3MBTL1 (0.41) | KMT2AMAPTFAAHGAAPOLB | |
| SCHEMBL23645434 | 0.76 | KMT2A (0.42) | KMT2AFAAHCYP1A2GAAADORA3 | |
| SCHEMBL19299941 | 0.73 | KMT2A (0.41) | KMT2AMAPTFAAHCYP1A2GAA | |
| SCHEMBL19284267 | 0.72 | KMT2A (0.40) | KMT2AFAAHCYP1A2GAAADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421225-B2 | Heteroaromatic amide derivative and medicament containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2025-09-23 | — | — | US | disclosed |
| CN-112689636-B | Novel heteroatom aromatic amide derivative and pharmaceutical agent containing same | 科研制药株式会社 | 2024-08-20 | — | — | CN | disclosed |
| EP-3851436-B1 | NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2024-06-12 | — | — | EP | disclosed |
| US-20230086366-A1 | Novel heteroaromatic amide derivative and medicament containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2023-03-23 | — | — | US | disclosed |
| EP-3851436-A1 | NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2021-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230086366-A1 | Novel heteroaromatic amide derivative and medicament containing the same | SCN7A, HCN4, SCN4A | KMT2A 1492/4885MAPT 4617/4885FAAH 435/4885 |
| US-12421225-B2 | Heteroaromatic amide derivative and medicament containing the same | SCN7A, HCN4, SCN4A | KMT2A 1413/4885MAPT 4572/4885FAAH 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.